Yes, research suggests that certain smell tests can help identify early signs of cognitive decline associated with Alzheimer’s disease, but they are not diagnostic tools on their own. Olfactory deficits—problems with the sense of smell—appear years before memory loss or other obvious symptoms, making them a potential early warning sign. A person who suddenly struggles to identify common odors like peppermint, fish, or rose may be at higher risk for Alzheimer’s, even if they feel mentally sharp and perform well on standard cognitive tests.
The connection between smell and Alzheimer’s is rooted in neurology. The olfactory bulb, the part of the brain that processes smell, is often among the first regions damaged by the protein plaques associated with Alzheimer’s disease. This means smell loss can precede cognitive symptoms by months or even years, offering a window for earlier detection and potential intervention before significant memory problems emerge.
Table of Contents
- How Do Smell Tests Detect Early Cognitive Changes?
- What Does the Current Research Show About Smell and Alzheimer’s?
- Why Smell Tests Cannot Diagnose Alzheimer’s Yet
- How Smell Tests Fit Into Current Dementia Screening Approaches
- Smell Loss Alone Is Not Reliable for Alzheimer’s Risk Assessment
- The Neuroscience Behind Olfactory Vulnerability in Alzheimer’s
- What to Do If You Notice Smell Changes
How Do Smell Tests Detect Early Cognitive Changes?
Smell tests used in research and clinical settings typically present a series of odors and ask patients to identify them from multiple choices. The University of Pennsylvania Smell Identification Test (UPSIT), which contains 40 odor trials, is one of the most common instruments. Patients scratch a labeled microencapsulated odor source and sniff, then select from four possible answers. Poor performance on this test—particularly difficulty identifying specific odors rather than general sensory loss—has been linked to cognitive impairment and Alzheimer’s risk. What makes olfactory testing different from other cognitive assessments is that it taps into a different neural pathway.
Standard cognitive tests measure memory, language, and reasoning directly. Smell tests measure whether the brain can process and identify sensory information from the olfactory system, which involves regions particularly vulnerable to Alzheimer’s pathology. Research has found that older adults who score poorly on smell identification tests are more likely to develop mild cognitive impairment within 5-10 years compared to those with normal smell function. The test itself is simple and inexpensive, which is why researchers have explored it as a potential screening tool. Unlike brain imaging (PET scans or MRI) or cerebrospinal fluid tests, a smell test requires no radiation, injection, or invasive procedure. This accessibility makes it theoretically useful for widespread screening, though clinical adoption remains limited.
What Does the Current Research Show About Smell and Alzheimer’s?
Multiple longitudinal studies have documented the association between olfactory dysfunction and Alzheimer’s disease. A 2017 meta-analysis found that people with smell identification deficits had about a threefold increased risk of developing Alzheimer’s compared to those with normal smell function over a follow-up period of 3-10 years. However, this elevated risk does not mean that everyone with smell loss will develop Alzheimer’s—the relationship is statistical, not deterministic. The strength of the connection varies depending on the population studied and how carefully researchers measured smell function. some studies in cognitively normal older adults showed smell deficits predicted future cognitive decline, while other research on people with existing mild cognitive impairment found that smell testing did not significantly improve prediction beyond other known risk factors.
This variability is an important limitation. Smell loss can also result from normal aging, chronic sinusitis, nasal polyps, COVID-19, smoking, or other unrelated causes, making it an imperfect early marker. Brain imaging studies have shown that people with poor smell identification tend to have more Alzheimer’s pathology—including amyloid and tau accumulation—in their brains, even when they show no cognitive symptoms. This finding supports the idea that smell loss may reflect underlying neuropathology, but the presence of pathology does not guarantee someone will develop dementia during their lifetime. Some people carry these brain changes without ever developing noticeable cognitive decline.
Why Smell Tests Cannot Diagnose Alzheimer’s Yet
The critical distinction is between an early indicator and a diagnostic tool. Smell tests show promise as a risk marker, but they cannot confirm Alzheimer’s disease on their own. Alzheimer’s diagnosis currently requires cognitive testing demonstrating memory or thinking problems, and confirmation only comes at autopsy through pathological examination of brain tissue. During life, doctors use cognitive assessments plus biomarker tests (blood tests for phosphorylated tau and amyloid, or CSF analysis, or PET imaging) to make a high-confidence diagnosis of Alzheimer’s. A major limitation is that not all people with smell loss develop Alzheimer’s, and not all people who develop Alzheimer’s show significant smell dysfunction early.
Some individuals with Alzheimer’s pathology maintain relatively normal smell function. Additionally, multiple other diseases and conditions can cause smell loss—Parkinson’s disease, Lewy body dementia, and other neurodegenerative conditions also affect olfaction, so a positive smell test does not point specifically to Alzheimer’s. A person might perform poorly on smell identification due to a chronic sinus infection, years of smoking, or simple age-related changes unrelated to brain disease. Clinical trials are underway to determine whether smell testing combined with other biomarkers might improve early detection. However, even if olfactory testing proves useful as part of a broader screening approach, it would likely never serve as a standalone diagnostic test.
How Smell Tests Fit Into Current Dementia Screening Approaches
Neurologists and geriatricians today do not routinely order formal smell identification tests as part of dementia screening, despite the research linking olfaction to Alzheimer’s risk. Instead, screening typically relies on cognitive questionnaires (like the Montreal Cognitive Assessment or Mini-Cog), sometimes supplemented by blood tests for biomarkers such as phosphorylated tau-181 and plasma phospho-tau217, which show stronger predictive accuracy than smell tests alone. These biomarkers can identify people at risk for cognitive decline with sensitivity and specificity exceeding 80%, whereas smell tests perform less reliably. However, smell assessment may eventually be incorporated into a multi-step screening process. Imagine a future workflow where a primary care doctor administers a quick smell test during an annual visit; if the patient performs poorly, it prompts more detailed cognitive screening and blood biomarker testing.
This layered approach could identify at-risk individuals without sending everyone for expensive neuroimaging. Some researchers are developing simplified or rapid smell tests that could be administered in a doctor’s office or even used in home-based screening programs. The challenge is establishing clinical value. To justify including a smell test in standard dementia screening, researchers would need to prove that identifying people with smell deficits actually improves outcomes—for instance, by allowing earlier intervention with disease-modifying therapies. Currently, disease-modifying Alzheimer’s treatments are limited and carry risks, so widespread screening is not yet routine in asymptomatic people. This may change if more effective treatments become available.
Smell Loss Alone Is Not Reliable for Alzheimer’s Risk Assessment
One serious limitation that deserves emphasis: smell dysfunction is common in older adults and has many causes unrelated to dementia. Approximately 25% of people over age 65 and 50% over age 80 experience some degree of olfactory decline, much of it due to normal aging of the olfactory system. Chronic rhinosinusitis affects up to 15% of the population and frequently impairs smell. A person who had COVID-19 may develop post-viral anosmia that persists for months or years. Heavy smokers often have impaired smell from nasal damage. None of these situations necessarily signals Alzheimer’s risk.
A critical warning: someone should not assume they are developing Alzheimer’s based solely on experiencing smell loss. Many treatable conditions cause this symptom. A person noticing new smell problems should first see their primary care doctor or an ear, nose, and throat specialist to rule out sinusitis, nasal obstruction, or other reversible causes. Only after those possibilities are excluded would smell dysfunction be considered as a potential marker of neurological change. Age, sex, and other factors also influence smell function in ways that complicate interpretation. Women generally have better smell than men at all ages, and genetics play a role in olfactory ability. Certain genetic variants associated with Alzheimer’s risk also correlate with smell deficits, making it unclear whether the olfactory change is a direct sign of neurodegeneration or simply a shared genetic trait.
The Neuroscience Behind Olfactory Vulnerability in Alzheimer’s
The olfactory bulb is unique because it is one of the few parts of the brain directly exposed to external antigens and potential pathogens. Some researchers theorize that Alzheimer’s pathology may begin in the olfactory system partly due to this exposure—perhaps to viruses or other triggers that accumulate in nasal tissue and seed amyloid or tau aggregation in the brain. This hypothesis remains speculative, but it explains why the olfactory system is so frequently affected early in the disease process.
The olfactory circuit also connects extensively to the entorhinal cortex and hippocampus—regions critical for memory. A small amount of damage in the olfactory bulb might not yet impair smell noticeably, but the same disease process spreading to the entorhinal cortex could trigger memory problems. This anatomical relationship supports the idea that olfactory decline precedes cognitive symptoms, though the progression is variable.
What to Do If You Notice Smell Changes
If an older adult or their family member experiences a noticeable change in smell—particularly sudden loss rather than gradual decline—discussing it with a doctor is reasonable, especially if there are other concerns about memory or thinking. The doctor can determine whether the smell loss has an obvious cause like sinus disease or medication side effects. If no clear cause is found and the person is concerned about dementia risk, formal cognitive screening can be offered, and blood biomarker testing is increasingly available.
For people who are cognitively normal but worried about Alzheimer’s risk, smell testing alone should not drive decisions about treatment or lifestyle changes. Age, family history, apolipoprotein E4 genetic status, cardiovascular health, cognitive reserve (education and mental stimulation), and sleep quality are all stronger established predictors of dementia risk. Focusing on modifiable factors—regular exercise, cognitive engagement, management of high blood pressure and cholesterol, quality sleep, and social connection—offers more immediate benefit than worrying about a smell test result.
- —
